OncoMatch/Clinical Trials/NCT07128641
Odronextamab in Low Tumor Volume Advanced FL
Is NCT07128641 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Odronextamab for follicular lymphoma.
Treatment: Odronextamab — The purpose of this study is to evaluate the safety and effectiveness of treating previously untreated Follicular Lymphoma (FL) with odronextamab. The name of the study drug in this research study is: -Odronextamab (a type of monoclonal antibody)
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20+ (by immunophenotype or immunohistochemistry) at time of diagnosis. All degrees of CD20 positivity will be accepted.)
follicular lymphoma grade 1-3A that is CD20+ (by immunophenotype or immunohistochemistry) at time of diagnosis. All degrees of CD20 positivity will be accepted.
Disease stage
Excluded: Stage I, LIMITED STAGE II
Grade: 123a
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy (rituximab, tazemetostat)
Patients who have had any prior systemic therapy for lymphoma, including rituximab and/or tazemetostat
Cannot have received: radiation therapy
Exception: Low dose radiotherapy RT (2x2Gy, or 4Gy x 1) is allowed but must be completed at least 12 weeks prior to treatment on this study; patients must meet criteria for measurable/assessable disease as outlined above after completion of RT, and have a nodal evaluable disease outside the radiation area
Patients who have had prior radiation therapy, with the following exception: Low dose radiotherapy RT (2x2Gy, or 4Gy x 1) is allowed but must be completed at least 12 weeks prior to treatment on this study
Lab requirements
Blood counts
Absolute neutrophil count ≥1000 cells/mcl; Platelets ≥100,000 cells/mcl; Hemoglobin ≥ 10 g/dL
Kidney function
Calculated creatinine clearance by Cockcroft Gault formula ≥40 mL/min
Liver function
Total bilirubin ≤1.5 × ULN (≤3 × ULN if attributed to lymphoma infiltration of liver); ALT and AST ≤3 × ULN (≤5 × ULN if attributed to lymphoma infiltration of liver); ALP ≤2.5 × ULN (≤5 × ULN if attributed to lymphoma infiltration of liver); exclusion if AST >3 × ULN and/or ALT >3 × ULN concurrent with total bilirubin >1.5 × ULN; Gilbert syndrome excluded if total bilirubin >4 × ULN
Cardiac function
Cardiac ejection fraction >40% by echocardiogram or MUGA scan
Participants must meet the following organ and marrow function as defined below: Absolute neutrophil count ≥1000 cells/mcl; Platelets ≥100,000 cells/mcl; Hemoglobin ≥ 10 g/dL; Cardiac ejection fraction >40% by echocardiogram or multi-gated acquisition (MUGA) scan; Total bilirubin ≤1.5 × ULN (≤3 × ULN if attributed to lymphoma infiltration of liver); ALT and AST ≤3 × ULN (≤5 × ULN if attributed to lymphoma infiltration of liver); ALP ≤2.5 × ULN (≤5 × ULN if attributed to lymphoma infiltration of liver); Calculated creatinine clearance by Cockcroft Gault formula ≥40 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify